[Immunological deficiency in patients with the myeloid forms of acute leukemia and the methods for its correction].
Immunologic and cytochemical studies were done in 162 patients with myeloid forms of acute leukosis, among whom 130 had acute myeloblastic leukemia (AML), and thirty two--and acute myelomonoblastic leukemia (AMML), before and after the therapy instituted. Immunocorrection was attempted with immunomodulating agents prodigiosane and tactivin. Striking inhibition of T-cellular immunity (T-total, T-active, TPhres, TPhsen, as well as blast transformation of lymphocytes with PHA) was revealed. All patients experienced significant rise in circulating immune complexes before treatment. Investigation designed to study intracellular metabolism of neutrophils demonstrated significant decline in the activities of G-6-P-ase, NAD- and NADP-oxidases, cationic proteins and NBT-test. Immunocorrective agents improve the state of immunologic reactivity, make for arresting infections and inflammatory processes and prolongation of remission in patients with acute myeloid forms of leukoses.
Gaĭdukova
S N
SN
Kindzel'skiĭ
A L
AL
Zverkova
A S
AS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic